<div class="page3 page">
    <div class="text-1"><img src="./assets/celltrion/03/title.png" alt=""></div>
    <div class="year-box">
        <div class="line"><img src="./assets/celltrion/03/line.png" alt=""></div>
        <div class="img-box">
            <div class="img-1 img"><img src="./assets/celltrion/03/img_01.png" alt=""></div>
            <div class="img-2 img"><img src="./assets/celltrion/03/img_02.png" alt=""></div>
            <div class="img-3 img"><img src="./assets/celltrion/03/img_03.png" alt=""></div>
            <div class="img-4 img"><img src="./assets/celltrion/03/img_04.png" alt=""></div>
        </div>
        <div class="c"><img src="./assets/celltrion/03/c.png" alt=""></div>
    </div>
    

    <div class="annotation">
        OmlycloÂ® (omalizumab) is licensed in the UK, however, will only be available upon patent expiry that is anticipated later this year.
    </div>
</div>